11/10/2025 | Press release | Distributed by Public on 11/10/2025 14:05
COPENHAGEN, Denmark, November 10, 2025 - Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4,94% of the shares and voting rights in Bavarian Nordic A/S as of November 4, 2025.
About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit https://www.bavarian-nordic.com.
Contact investors:Europe: Disa Tuominen, IR Manager, [email protected]: Graham Morrell, Gilmartin Group, [email protected], Tel: +1 781 686 9600
Contact media:Nicole Seroff, Vice President Corporate Communications, [email protected], Tel: +45 53 88 06 03
Company Announcement no. 42 / 2025
Attachment